US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

35.17

+0.24000.69%

Post-market: 35.810.6425+1.83%19:44 EDT

Volume:320.74K

Turnover:11.18M

Market Cap:2.46B

PE:-11.75

High:35.97

Open:35.05

Low:34.04

Close:34.93

52wk High:38.13

52wk Low:20.65

Shares:69.86M

Float Shares:43.70M

Volume Ratio:0.61

T/O Rate:0.73%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.9943

EPS(LYR):-3.4871

ROE:-70.46%

ROA:-42.32%

PB:7.05

PE(LYR):-10.09

Loading ...

Overview Company News Filings

Pharvaris Is Maintained at Outperform by Wedbush

Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says

MT Newswires Live

Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder

Benzinga_recent_news

Pharvaris NV reports results for the quarter ended December 31 - Earnings Summary

RBC Trims Price Target on Pharvaris to $51 From $52, Keeps Outperform, Speculative Risk

MT Newswires Live

Does CHAPTER-3 Enrollment Milestone and Pipeline Progress Change The Bull Case For Pharvaris (PHVS)?

Simply Wall St.

Pharvaris NV expected to post a loss of 70 cents a share - Earnings Preview

Top Premarket Decliners

MT Newswires Live

Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data

Pharvaris Q4 EPS $(0.84) Misses $(0.69) Estimate

Benzinga Earnings

Earnings Flash (PHVS) Pharvaris Posts Q4 Loss 0.72 Euro a Share

MT Newswires Live

Pharvaris FY25 loss widens to €176 million; Q4 loss climbs to €46.7 million

Pharvaris Nv - FY2025 Loss €176 Mln; Basic and Diluted Loss per Share €2.97

THOMSON REUTERS

Press Release: Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Assessing Pharvaris (PHVS) Valuation After Recent Share Price Pullback And Strong Longer Term Returns

Simply Wall St.

BioCryst Shares Remain Undervalued, RBC Says

MT Newswires Live

Is It Too Late To Consider Pharvaris (PHVS) After A 3.5x Three Year Surge?

Simply Wall St.

Pharvaris announces publications of efficacy, safety evidence on deucrictibant

Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema

Pharvaris NV director Robert Glassman files initial beneficial ownership statement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/PHVS/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PHVS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PHVS\",,,,,undefined,":{"symbol":"PHVS","market":"US","secType":"STK","nameCN":"Pharvaris N.V.","latestPrice":35.17,"timestamp":1788379200000,"preClose":34.93,"halted":0,"volume":320740,"hourTrading":{"tag":"盘后","latestPrice":35.8125,"preClose":35.17,"latestTime":"19:44 EDT","volume":1786,"amount":63498.104499999994,"timestamp":1788392697216,"change":0.6425,"changeRate":0.018268,"amplitude":0.028433},"delay":0,"changeRate":0.006870884626395705,"floatShares":43698700,"shares":69863685,"eps":-2.994346,"marketStatus":"Post-Mkt","change":0.24,"latestTime":"09-02 19:45:06 EDT","open":35.05,"high":35.97,"low":34.04,"amount":11182814.9958,"amplitude":0.055253,"askPrice":36.5,"askSize":1,"bidPrice":35.09,"bidSize":140,"shortable":3,"etf":0,"ttmEps":-2.994346,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788393600000},"marketStatusCode":4,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":34.93,"preHourTrading":{"tag":"盘前","latestPrice":34.92,"preClose":34.93,"latestTime":"09:28 EDT","volume":149,"amount":5169.04244,"timestamp":1788355680063,"change":-0.01,"changeRate":-0.000286,"amplitude":0.029559},"postHourTrading":{"tag":"盘后","latestPrice":35.8125,"preClose":35.17,"latestTime":"19:44 EDT","volume":1786,"amount":63498.104499999994,"timestamp":1788392697216,"change":0.6425,"changeRate":0.018268,"amplitude":0.028433},"volumeRatio":0.606321,"optionData":{"bulkOrders":[{"symbol":"PHVS","call":true,"expireDate":1789704000000,"strike":"50.0","timestamp":1788369709251,"price":0.8,"volume":2000,"amount":160000,"type":"-"}]},"impliedVol":1.2915,"impliedVolPercentile":0.9395},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PHVS\",,,,,undefined,":{"symbol":"PHVS","floatShares":43698700,"roa":"-42.32%","roe":"-70.46%","lyrEps":-3.487143,"volumeRatio":0.606321,"shares":69863685,"dividePrice":0,"high":35.97,"amplitude":0.055253,"preClose":34.93,"low":34.04,"week52Low":20.65,"pbRate":"7.05","week52High":38.13,"institutionHeld":0,"latestPrice":35.17,"committee":0.985816,"eps":-2.994346,"divideRate":0,"volume":320740,"delay":0,"ttmEps":-2.994346,"open":35.05,"prevYearClose":27.75,"prevWeekClose":35.32,"prevMonthClose":34.61,"prevQuarterClose":34.58,"fiveDayClose":37,"twentyDayClose":33.42,"sixtyDayClose":31.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PHVS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"PHVS","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"pre","actualEps":-0.81},{"market":"US","date":"2026-05-12","symbol":"PHVS","fiscalQuarterEnding":"2026/03","expectedEps":-0.76,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.7},{"market":"US","date":"2026-04-02","symbol":"PHVS","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1775102400000,"reportTimeType":"pre","actualEps":-0.84},{"market":"US","date":"2025-11-12","symbol":"PHVS","fiscalQuarterEnding":"2025/09","expectedEps":-0.78,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.7},{"market":"US","date":"2025-08-12","symbol":"PHVS","fiscalQuarterEnding":"2025/06","expectedEps":-0.87,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.94}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PHVS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PHVS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4667,"buy":0.4667,"hold":0.0667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4667,"analysts":15,"updateTime":1784174400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PHVS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PHVS","date":"2026-09-01","current":-11.74547,"percent":0.176664,"low":-16.528573,"twenty":-12.094187,"median":-8.622235,"eighty":-5.917471,"high":-1.271834,"avg":-8.826596,"sd":3.16724,"marketCap":2429777952},"quantilePoints":[{"date":"2021-09-03","current":-13.869765,"twenty":-41.690069,"median":-21.159134,"eighty":-14.206363,"marketCap":629774552},{"date":"2021-09-10","current":-14.483783,"twenty":-41.636401,"median":-21.097683,"eighty":-14.200739,"marketCap":654620997},{"date":"2021-09-17","current":-13.408551,"twenty":-41.415194,"median":-19.619941,"eighty":-14.095163,"marketCap":601399913},{"date":"2021-09-24","current":-13.735189,"twenty":-41.105195,"median":-19.412718,"eighty":-13.917369,"marketCap":614535400},{"date":"2021-10-01","current":-13.275187,"twenty":-41.073352,"median":-19.361573,"eighty":-13.752501,"marketCap":588032525},{"date":"2021-10-08","current":-11.567624,"twenty":-40.951984,"median":-19.206349,"eighty":-13.609193,"marketCap":511505475},{"date":"2021-10-15","current":-11.808567,"twenty":-40.76486,"median":-19.158657,"eighty":-13.358075,"marketCap":523431769},{"date":"2021-10-22","current":-11.367098,"twenty":-40.543106,"median":-18.996962,"eighty":-13.26419,"marketCap":505211043},{"date":"2021-10-29","current":-13.069107,"twenty":-40.31092,"median":-18.615071,"eighty":-13.235325,"marketCap":577431375},{"date":"2021-11-05","current":-11.318661,"twenty":-40.118706,"median":-18.174436,"eighty":-12.989342,"marketCap":499744825},{"date":"2021-11-12","current":-12.526544,"twenty":-39.882961,"median":-18.037659,"eighty":-12.809718,"marketCap":547946928},{"date":"2021-11-19","current":-11.924212,"twenty":-39.73926,"median":-17.467833,"eighty":-12.433857,"marketCap":515812193},{"date":"2021-11-26","current":-10.362749,"twenty":-39.575288,"median":-16.707882,"eighty":-12.294384,"marketCap":448064220},{"date":"2021-12-03","current":-11.26034,"twenty":-38.958466,"median":-15.822297,"eighty":-12.166304,"marketCap":485665173},{"date":"2021-12-10","current":-11.449501,"twenty":-38.90261,"median":-15.106412,"eighty":-12.085176,"marketCap":494941179},{"date":"2021-12-17","current":-11.918983,"twenty":-38.786622,"median":-14.824901,"eighty":-12.032102,"marketCap":513493191},{"date":"2021-12-23","current":-12.067526,"twenty":-38.613439,"median":-14.809703,"eighty":-12.04158,"marketCap":521775339},{"date":"2021-12-31","current":-10.970608,"twenty":-38.556139,"median":-14.6624,"eighty":-12.029733,"marketCap":476720453},{"date":"2022-01-07","current":-14.755715,"twenty":-38.260176,"median":-14.556631,"eighty":-12.04158,"marketCap":639381844},{"date":"2022-01-14","current":-13.648303,"twenty":-37.900499,"median":-14.301086,"eighty":-12.059144,"marketCap":595652102},{"date":"2022-01-21","current":-13.462107,"twenty":-37.887735,"median":-14.301086,"eighty":-12.06585,"marketCap":583394522},{"date":"2022-01-28","current":-13.205088,"twenty":-37.172324,"median":-14.201073,"eighty":-12.067932,"marketCap":563186081},{"date":"2022-02-04","current":-13.024782,"twenty":-36.626254,"median":-14.120681,"eighty":-12.079807,"marketCap":569480513},{"date":"2022-02-11","current":-13.759795,"twenty":-36.368387,"median":-14.065459,"eighty":-12.092451,"marketCap":599627533},{"date":"2022-02-18","current":-13.388638,"twenty":-36.150333,"median":-14.023379,"eighty":-12.098608,"marketCap":579750377},{"date":"2022-02-25","current":-13.305926,"twenty":-35.845851,"median":-13.954525,"eighty":-12.116084,"marketCap":572793372},{"date":"2022-03-04","current":-14.115965,"twenty":-35.670778,"median":-13.938377,"eighty":-12.137788,"marketCap":588695097},{"date":"2022-03-11","current":-13.463028,"twenty":-34.421493,"median":-13.892451,"eighty":-12.149516,"marketCap":563186081},{"date":"2022-03-18","current":-14.218002,"twenty":-29.632768,"median":-13.881977,"eighty":-12.157248,"marketCap":600952677},{"date":"2022-03-25","current":-13.943073,"twenty":-26.658074,"median":-13.883771,"eighty":-12.178203,"marketCap":585382238},{"date":"2022-04-01","current":-12.747151,"twenty":-26.362243,"median":-13.880091,"eighty":-12.194172,"marketCap":601209361},{"date":"2022-04-08","current":-13.160374,"twenty":-26.219887,"median":-13.869765,"eighty":-12.198767,"marketCap":611652204},{"date":"2022-04-14","current":-12.64181,"twenty":-26.010325,"median":-13.786628,"eighty":-12.200601,"marketCap":583804624},{"date":"2022-04-22","current":-12.23556,"twenty":-25.770465,"median":-13.764494,"eighty":-12.203958,"marketCap":563581977},{"date":"2022-04-29","current":-12.580911,"twenty":-25.660418,"median":-13.730786,"eighty":-12.217679,"marketCap":566542439},{"date":"2022-05-06","current":-12.310085,"twenty":-25.093495,"median":-13.707219,"eighty":-12.233824,"marketCap":557283119},{"date":"2022-05-13","current":-10.422165,"twenty":-24.148325,"median":-13.655613,"eighty":-12.198139,"marketCap":571878572},{"date":"2022-05-20","current":-10.134271,"twenty":-23.650401,"median":-13.608097,"eighty":-12.152353,"marketCap":563590477},{"date":"2022-05-27","current":-10.266885,"twenty":-23.509475,"median":-13.570194,"eighty":-12.096742,"marketCap":579835143},{"date":"2022-06-03","current":-10.984203,"twenty":-23.463638,"median":-13.4682,"eighty":-12.07039,"marketCap":620612572},{"date":"2022-06-10","current":-12.843347,"twenty":-23.155882,"median":-13.459721,"eighty":-12.067627,"marketCap":712444667},{"date":"2022-06-17","current":-16.528573,"twenty":-22.410251,"median":-13.457335,"eighty":-12.07039,"marketCap":911690477},{"date":"2022-06-24","current":-12.484354,"twenty":-22.307498,"median":-13.442896,"eighty":-12.079819,"marketCap":694210858},{"date":"2022-07-01","current":-14.299351,"twenty":-21.874535,"median":-13.402807,"eighty":-12.068033,"marketCap":784053810},{"date":"2022-07-08","current":-14.094213,"twenty":-21.750061,"median":-13.450115,"eighty":-12.077462,"marketCap":756209125},{"date":"2022-07-15","current":-14.396825,"twenty":-21.331431,"median":-13.463028,"eighty":-12.082165,"marketCap":765820001},{"date":"2022-07-22","current":-13.29424,"twenty":-21.174218,"median":-13.473474,"eighty":-12.092451,"marketCap":716422953},{"date":"2022-07-29","current":-13.469033,"twenty":-21.125909,"median":-13.4682,"eighty":-12.098608,"marketCap":724213762},{"date":"2022-08-05","current":-11.76507,"twenty":-21.101667,"median":-13.459721,"eighty":-12.082165,"marketCap":629895239},{"date":"2022-08-12","current":-10.43948,"twenty":-20.186916,"median":-13.408551,"eighty":-12.055631,"marketCap":564253524},{"date":"2022-08-19","current":-11.581834,"twenty":-19.826532,"median":-13.395996,"eighty":-12.028713,"marketCap":612987524},{"date":"2022-08-26","current":-5.820227,"twenty":-19.515891,"median":-13.372919,"eighty":-11.990749,"marketCap":306659524},{"date":"2022-09-02","current":-5.892736,"twenty":-19.429171,"median":-13.356682,"eighty":-11.943475,"marketCap":311632381},{"date":"2022-09-09","current":-5.834763,"twenty":-19.417564,"median":-13.345814,"eighty":-11.915113,"marketCap":308814429},{"date":"2022-09-16","current":-6.129031,"twenty":-19.393433,"median":-13.317212,"eighty":-11.844209,"marketCap":307945619},{"date":"2022-09-23","current":-5.527907,"twenty":-19.377706,"median":-13.304479,"eighty":-11.805952,"marketCap":269452416},{"date":"2022-09-30","current":-5.268219,"twenty":-19.358729,"median":-13.29424,"eighty":-11.739355,"marketCap":258984966},{"date":"2022-10-07","current":-3.334511,"twenty":-19.313349,"median":-13.281408,"eighty":-11.574558,"marketCap":163427280},{"date":"2022-10-14","current":-3.192899,"twenty":-19.240081,"median":-13.26552,"eighty":-11.519941,"marketCap":155998767},{"date":"2022-10-21","current":-3.776992,"twenty":-19.189017,"median":-13.2607,"eighty":-11.419826,"marketCap":185712818},{"date":"2022-10-28","current":-3.404363,"twenty":-19.175941,"median":-13.241782,"eighty":-11.34035,"marketCap":169704373},{"date":"2022-11-04","current":-2.493588,"twenty":-19.155403,"median":-13.21909,"eighty":-11.293284,"marketCap":123921098},{"date":"2022-11-11","current":-1.962841,"twenty":-19.119693,"median":-13.202703,"eighty":-11.220822,"marketCap":101635560},{"date":"2022-11-18","current":-1.709372,"twenty":-19.040002,"median":-13.169144,"eighty":-11.073401,"marketCap":88804493},{"date":"2022-11-25","current":-1.59989,"twenty":-18.960552,"median":-13.089194,"eighty":-10.924331,"marketCap":83401938},{"date":"2022-12-02","current":-1.271834,"twenty":-18.879299,"median":-13.066255,"eighty":-10.549888,"marketCap":66856614},{"date":"2022-12-09","current":-5.585763,"twenty":-18.659925,"median":-13.055482,"eighty":-10.38824,"marketCap":291250318},{"date":"2022-12-16","current":-4.830297,"twenty":-18.384979,"median":-13.024782,"eighty":-10.32247,"marketCap":253408050},{"date":"2022-12-23","current":-6.371604,"twenty":-18.295522,"median":-12.990589,"eighty":-10.187317,"marketCap":334836503},{"date":"2022-12-30","current":-7.188594,"twenty":-18.170479,"median":-12.982972,"eighty":-10.008759,"marketCap":380112075},{"date":"2023-01-06","current":-7.688928,"twenty":-18.154652,"median":-12.903124,"eighty":-9.752954,"marketCap":403763493},{"date":"2023-01-13","current":-5.706058,"twenty":-18.104257,"median":-12.846213,"eighty":-7.688928,"marketCap":305441169},{"date":"2023-01-20","current":-6.459312,"twenty":-17.9977,"median":-12.837332,"eighty":-7.374204,"marketCap":346324335},{"date":"2023-01-27","current":-5.951135,"twenty":-17.857094,"median":-12.821298,"eighty":-6.862976,"marketCap":319632020},{"date":"2023-02-03","current":-5.776873,"twenty":-17.539987,"median":-12.756949,"eighty":-6.367933,"marketCap":310171453},{"date":"2023-02-10","current":-6.06212,"twenty":-17.052096,"median":-12.693639,"eighty":-6.243368,"marketCap":320307775},{"date":"2023-02-17","current":-5.565251,"twenty":-16.755938,"median":-12.64181,"eighty":-6.151395,"marketCap":293615460},{"date":"2023-02-24","current":-5.080906,"twenty":-16.600297,"median":-12.612561,"eighty":-6.08797,"marketCap":265233759},{"date":"2023-03-03","current":-5.604926,"twenty":-16.439572,"median":-12.581052,"eighty":-6.019199,"marketCap":293953338},{"date":"2023-03-10","current":-4.059398,"twenty":-16.126823,"median":-12.554737,"eighty":-5.957727,"marketCap":214214271},{"date":"2023-03-17","current":-4.759844,"twenty":-15.898426,"median":-12.5386,"eighty":-5.915214,"marketCap":251042908},{"date":"2023-03-24","current":-4.748457,"twenty":-15.814998,"median":-12.484354,"eighty":-5.839251,"marketCap":252732295},{"date":"2023-03-31","current":-5.062872,"twenty":-15.558556,"median":-12.41617,"eighty":-5.818726,"marketCap":272160245},{"date":"2023-04-06","current":-5.515395,"twenty":-15.2868,"median":-12.393076,"eighty":-5.798276,"marketCap":298007866},{"date":"2023-04-14","current":-3.407139,"twenty":-15.104598,"median":-12.376683,"eighty":-5.751686,"marketCap":287439901},{"date":"2023-04-21","current":-3.423024,"twenty":-15.075219,"median":-12.365371,"eighty":-5.695738,"marketCap":286594490},{"date":"2023-04-28","current":-3.621546,"twenty":-14.971826,"median":-12.310085,"eighty":-5.661512,"marketCap":304686295},{"date":"2023-05-05","current":-3.635585,"twenty":-14.858222,"median":-12.26867,"eighty":-5.593428,"marketCap":305362624},{"date":"2023-05-12","current":-3.330904,"twenty":-14.826016,"median":-12.249364,"eighty":-5.568587,"marketCap":277633128},{"date":"2023-05-19","current":-3.332274,"twenty":-14.818952,"median":-12.234113,"eighty":-5.5204,"marketCap":297584839},{"date":"2023-05-26","current":-3.231497,"twenty":-14.811441,"median":-12.222059,"eighty":-5.439393,"marketCap":287439901},{"date":"2023-06-02","current":-3.434585,"twenty":-14.791955,"median":-12.201472,"eighty":-5.312927,"marketCap":305832502},{"date":"2023-06-09","current":-3.407273,"twenty":-14.764775,"median":-12.198453,"eighty":-5.28475,"marketCap":304479261},{"date":"2023-06-16","current":-4.170938,"twenty":-14.740265,"median":-12.160354,"eighty":-5.07843,"marketCap":377892593},{"date":"2023-06-23","current":-4.359744,"twenty":-14.731325,"median":-12.152393,"eighty":-5.057591,"marketCap":396297439},{"date":"2023-06-30","current":-7.00064,"twenty":-14.718305,"median":-12.136009,"eighty":-5.055831,"marketCap":632126719},{"date":"2023-07-07","current":-7.084548,"twenty":-14.696694,"median":-12.097209,"eighty":-5.062872,"marketCap":638244074},{"date":"2023-07-14","current":-6.875228,"twenty":-14.6624,"median":-12.079819,"eighty":-5.068525,"marketCap":638244074},{"date":"2023-07-21","current":-7.028003,"twenty":-14.653302,"median":-12.064139,"eighty":-5.080906,"marketCap":649663138},{"date":"2023-07-28","current":-7.498848,"twenty":-14.622905,"median":-12.04158,"eighty":-5.207419,"marketCap":683512504},{"date":"2023-08-04","current":-7.953511,"twenty":-14.601036,"median":-12.024634,"eighty":-5.228713,"marketCap":722255754},{"date":"2023-08-11","current":-7.354477,"twenty":-14.583407,"median":-11.998532,"eighty":-5.261383,"marketCap":747059362},{"date":"2023-08-18","current":-7.862758,"twenty":-14.572779,"median":-11.956319,"eighty":-5.28475,"marketCap":788698737},{"date":"2023-08-25","current":-7.637624,"twenty":-14.506463,"median":-11.943194,"eighty":-5.298861,"marketCap":762796904},{"date":"2023-08-31","current":-8.133422,"twenty":-14.4867,"median":-11.921598,"eighty":-5.305964,"marketCap":813459365},{"date":"2023-09-08","current":-7.866907,"twenty":-14.484166,"median":-11.909309,"eighty":-5.312927,"marketCap":776279656},{"date":"2023-09-15","current":-8.565073,"twenty":-14.483879,"median":-11.869315,"eighty":-5.324599,"marketCap":842467710},{"date":"2023-09-22","current":-8.218785,"twenty":-14.422991,"median":-11.843691,"eighty":-5.364732,"marketCap":808147978},{"date":"2023-09-29","current":-8.499622,"twenty":-14.407261,"median":-11.810464,"eighty":-5.391254,"marketCap":828167822},{"date":"2023-10-06","current":-8.075664,"twenty":-14.404891,"median":-11.805298,"eighty":-5.421144,"marketCap":784042452},{"date":"2023-10-13","current":-7.97887,"twenty":-14.393189,"median":-11.762441,"eighty":-5.494747,"marketCap":776279656},{"date":"2023-10-20","current":-7.871535,"twenty":-14.374592,"median":-11.67635,"eighty":-5.497417,"marketCap":767699722},{"date":"2023-10-27","current":-7.699507,"twenty":-14.37054,"median":-11.628617,"eighty":-5.497654,"marketCap":747679879},{"date":"2023-11-03","current":-7.17043,"twenty":-14.351862,"median":-11.573402,"eighty":-5.505177,"marketCap":701920236},{"date":"2023-11-10","current":-5.970942,"twenty":-14.325681,"median":-11.546094,"eighty":-5.518658,"marketCap":686476556},{"date":"2023-11-17","current":-5.487665,"twenty":-14.300392,"median":-11.499199,"eighty":-5.518658,"marketCap":639755166},{"date":"2023-11-24","current":-5.931936,"twenty":-14.283081,"median":-11.456561,"eighty":-5.501771,"marketCap":694263454},{"date":"2023-12-01","current":-6.025826,"twenty":-14.216157,"median":-11.367098,"eighty":-5.517027,"marketCap":705329046},{"date":"2023-12-08","current":-11.439876,"twenty":-14.20757,"median":-11.347894,"eighty":-5.524424,"marketCap":1324602518},{"date":"2023-12-15","current":-11.41059,"twenty":-14.202076,"median":-11.375314,"eighty":-5.532271,"marketCap":1346488162},{"date":"2023-12-22","current":-11.925452,"twenty":-14.184853,"median":-11.42744,"eighty":-5.551316,"marketCap":1406934225},{"date":"2023-12-29","current":-12.247032,"twenty":-14.141201,"median":-11.449501,"eighty":-5.556079,"marketCap":1455916379},{"date":"2024-01-05","current":-11.217845,"twenty":-14.124263,"median":-11.444688,"eighty":-5.560701,"marketCap":1319391651},{"date":"2024-01-12","current":-13.194311,"twenty":-14.118795,"median":-11.460366,"eighty":-5.568587,"marketCap":1550325393},{"date":"2024-01-19","current":-14.465426,"twenty":-14.174814,"median":-11.47464,"eighty":-5.574125,"marketCap":1686754028},{"date":"2024-01-26","current":-14.983944,"twenty":-14.20757,"median":-11.499199,"eighty":-5.577066,"marketCap":1742861042},{"date":"2024-02-02","current":-15.192524,"twenty":-14.300739,"median":-11.528223,"eighty":-5.581389,"marketCap":1768847449},{"date":"2024-02-09","current":-14.748842,"twenty":-14.393189,"median":-11.54682,"eighty":-5.589596,"marketCap":1703881432},{"date":"2024-02-16","current":-13.65194,"twenty":-14.404891,"median":-11.567624,"eighty":-5.608959,"marketCap":1576311800},{"date":"2024-02-23","current":-14.13304,"twenty":-14.396825,"median":-11.581834,"eighty":-5.625092,"marketCap":1640687216},{"date":"2024-03-01","current":-10.303743,"twenty":-14.378644,"median":-11.573402,"eighty":-5.629721,"marketCap":1195373004},{"date":"2024-03-08","current":-12.093153,"twenty":-14.358385,"median":-11.567624,"eighty":-5.636181,"marketCap":1418455194},{"date":"2024-03-15","current":-10.896325,"twenty":-14.342077,"median":-11.552539,"eighty":-5.658684,"marketCap":1273758779},{"date":"2024-03-22","current":-11.538805,"twenty":-14.301086,"median":-11.546205,"eighty":-5.665753,"marketCap":1344762225},{"date":"2024-03-28","current":-10.904189,"twenty":-14.299698,"median":-11.538805,"eighty":-5.674035,"marketCap":1264076491},{"date":"2024-04-05","current":-10.349243,"twenty":-14.288877,"median":-11.507756,"eighty":-5.680711,"marketCap":1206520668},{"date":"2024-04-12","current":-11.107813,"twenty":-14.231653,"median":-11.490879,"eighty":-5.687459,"marketCap":1200065809},{"date":"2024-04-19","current":-9.215802,"twenty":-14.210621,"median":-11.46913,"eighty":-5.702618,"marketCap":991303742},{"date":"2024-04-26","current":-11.339937,"twenty":-14.20395,"median":-11.459096,"eighty":-5.715476,"marketCap":1225406418},{"date":"2024-05-03","current":-11.733497,"twenty":-14.200071,"median":-11.46913,"eighty":-5.724599,"marketCap":1266307115},{"date":"2024-05-10","current":-9.668623,"twenty":-14.189365,"median":-11.459096,"eighty":-5.733174,"marketCap":1107009662},{"date":"2024-05-17","current":-10.115404,"twenty":-14.156013,"median":-11.42744,"eighty":-5.759289,"marketCap":1168360708},{"date":"2024-05-24","current":-9.147602,"twenty":-14.136092,"median":-11.375314,"eighty":-5.774576,"marketCap":1052116621},{"date":"2024-05-31","current":-8.827191,"twenty":-14.129207,"median":-11.35501,"eighty":-5.782121,"marketCap":1017135762},{"date":"2024-06-07","current":-7.823819,"twenty":-14.123069,"median":-11.339823,"eighty":-5.787829,"marketCap":904658844},{"date":"2024-06-14","current":-8.515887,"twenty":-14.119026,"median":-11.316994,"eighty":-5.792437,"marketCap":974082396},{"date":"2024-06-21","current":-8.52603,"twenty":-14.116428,"median":-11.288753,"eighty":-5.797709,"marketCap":970853394},{"date":"2024-06-28","current":-8.52006,"twenty":-14.116197,"median":-11.262481,"eighty":-5.798843,"marketCap":969238893},{"date":"2024-07-05","current":-7.963908,"twenty":-14.11303,"median":-11.251924,"eighty":-5.805313,"marketCap":914884019},{"date":"2024-07-12","current":-8.497692,"twenty":-14.104041,"median":-11.224936,"eighty":-5.814579,"marketCap":981616735},{"date":"2024-07-15","current":-8.709438,"twenty":-14.101747,"median":-11.224715,"eighty":-5.815211,"marketCap":1010139590},{"date":"2024-08-02","current":-7.485095,"twenty":-14.099454,"median":-11.224493,"eighty":-5.815842,"marketCap":857838309},{"date":"2024-08-09","current":-7.640912,"twenty":-14.094802,"median":-11.205504,"eighty":-5.819476,"marketCap":885822997},{"date":"2024-08-16","current":-8.240501,"twenty":-14.093907,"median":-11.162588,"eighty":-5.823431,"marketCap":1032742607},{"date":"2024-08-23","current":-7.760367,"twenty":-14.048436,"median":-11.118035,"eighty":-5.826337,"marketCap":983480417},{"date":"2024-08-30","current":-7.393035,"twenty":-14.034683,"median":-11.087899,"eighty":-5.833183,"marketCap":934333400},{"date":"2024-09-06","current":-8.155019,"twenty":-14.033224,"median":-11.020127,"eighty":-5.839251,"marketCap":1031547280},{"date":"2024-09-13","current":-8.802104,"twenty":-14.027088,"median":-10.978779,"eighty":-5.849019,"marketCap":1108238229},{"date":"2024-09-20","current":-8.962749,"twenty":-13.99324,"median":-10.957045,"eighty":-5.877056,"marketCap":1139022624},{"date":"2024-09-27","current":-8.000083,"twenty":-13.961974,"median":-10.894902,"eighty":-5.894802,"marketCap":1020205660},{"date":"2024-10-04","current":-7.688355,"twenty":-13.947654,"median":-10.874176,"eighty":-5.909483,"marketCap":966197949},{"date":"2024-10-11","current":-7.725025,"twenty":-13.936046,"median":-10.812773,"eighty":-5.924083,"marketCap":962957487},{"date":"2024-10-18","current":-9.289256,"twenty":-13.925882,"median":-10.792815,"eighty":-5.928401,"marketCap":1147663858},{"date":"2024-10-25","current":-9.347449,"twenty":-13.904362,"median":-10.773913,"eighty":-5.930655,"marketCap":1151984475},{"date":"2024-10-31","current":-10.81176,"twenty":-13.888979,"median":-10.69668,"eighty":-5.935928,"marketCap":1339391232},{"date":"2024-11-08","current":-9.795031,"twenty":-13.882336,"median":-10.614452,"eighty":-5.945603,"marketCap":1205452109},{"date":"2024-11-15","current":-7.934741,"twenty":-13.880109,"median":-10.567811,"eighty":-5.951569,"marketCap":1109858461},{"date":"2024-11-22","current":-8.193559,"twenty":-13.878421,"median":-10.530141,"eighty":-5.955891,"marketCap":1136322239},{"date":"2024-11-29","current":-8.515548,"twenty":-13.874795,"median":-10.499116,"eighty":-5.962822,"marketCap":1187704999},{"date":"2024-12-06","current":-7.575701,"twenty":-13.869107,"median":-10.430822,"eighty":-5.969,"marketCap":1058630209},{"date":"2024-12-13","current":-7.438607,"twenty":-13.864864,"median":-10.405945,"eighty":-5.972,"marketCap":1031513657},{"date":"2024-12-20","current":-7.511117,"twenty":-13.847086,"median":-10.370165,"eighty":-5.976517,"marketCap":1030971326},{"date":"2024-12-27","current":-7.680726,"twenty":-13.801742,"median":-10.357252,"eighty":-5.977661,"marketCap":1057545547},{"date":"2025-01-03","current":-7.415916,"twenty":-13.792864,"median":-10.345951,"eighty":-6.00833,"marketCap":1005481766},{"date":"2025-01-10","current":-7.387777,"twenty":-13.788234,"median":-10.323543,"eighty":-6.019199,"marketCap":1005481766},{"date":"2025-01-17","current":-6.953437,"twenty":-13.781733,"median":-10.297117,"eighty":-6.023626,"marketCap":946367682},{"date":"2025-01-24","current":-7.612205,"twenty":-13.774759,"median":-10.284647,"eighty":-6.025423,"marketCap":1047783588},{"date":"2025-01-31","current":-6.977006,"twenty":-13.765434,"median":-10.25901,"eighty":-6.034301,"marketCap":961552951},{"date":"2025-02-07","current":-7.219276,"twenty":-13.753463,"median":-10.232674,"eighty":-6.052543,"marketCap":990296497},{"date":"2025-02-14","current":-6.822516,"twenty":-13.740454,"median":-10.115609,"eighty":-6.061351,"marketCap":942029033},{"date":"2025-02-21","current":-6.467941,"twenty":-13.734308,"median":-10.093087,"eighty":-6.062421,"marketCap":894846232},{"date":"2025-02-28","current":-6.133931,"twenty":-13.727465,"median":-10.02417,"eighty":-6.065143,"marketCap":843867113},{"date":"2025-03-07","current":-5.852269,"twenty":-13.71316,"median":-9.970579,"eighty":-6.049778,"marketCap":837901472},{"date":"2025-03-14","current":-6.385184,"twenty":-13.708332,"median":-9.910974,"eighty":-6.026825,"marketCap":917081805},{"date":"2025-03-21","current":-5.844642,"twenty":-13.700767,"median":-9.829627,"eighty":-6.025288,"marketCap":838443803},{"date":"2025-03-28","current":-5.916884,"twenty":-13.679442,"median":-9.795031,"eighty":-5.984934,"marketCap":844409444},{"date":"2025-04-04","current":-5.41793,"twenty":-13.665275,"median":-9.712775,"eighty":-5.969,"marketCap":792887995},{"date":"2025-04-11","current":-4.319691,"twenty":-13.654878,"median":-9.636637,"eighty":-5.953745,"marketCap":648468389},{"date":"2025-04-17","current":-4.898467,"twenty":-13.65194,"median":-9.603412,"eighty":-5.931936,"marketCap":747645908},{"date":"2025-04-25","current":-5.660159,"twenty":-13.648303,"median":-9.484661,"eighty":-5.916884,"marketCap":862626437},{"date":"2025-05-02","current":-6.426634,"twenty":-13.611466,"median":-9.396394,"eighty":-5.918352,"marketCap":972702584},{"date":"2025-05-09","current":-6.135697,"twenty":-13.604729,"median":-9.345786,"eighty":-5.927903,"marketCap":928563139},{"date":"2025-05-16","current":-5.081075,"twenty":-13.598948,"median":-9.280564,"eighty":-5.916884,"marketCap":866985889},{"date":"2025-05-23","current":-5.189286,"twenty":-13.570194,"median":-9.208581,"eighty":-5.882056,"marketCap":893142597},{"date":"2025-05-30","current":-5.256736,"twenty":-13.527456,"median":-9.173722,"eighty":-5.851134,"marketCap":911125334},{"date":"2025-06-06","current":-5.007101,"twenty":-13.509055,"median":-9.060878,"eighty":-5.837961,"marketCap":874614929},{"date":"2025-06-13","current":-5.317982,"twenty":-13.49872,"median":-8.982791,"eighty":-5.819476,"marketCap":938916836},{"date":"2025-06-20","current":-5.183436,"twenty":-13.485895,"median":-8.943559,"eighty":-5.800161,"marketCap":906765882},{"date":"2025-06-27","current":-5.465947,"twenty":-13.472919,"median":-8.879507,"eighty":-5.782121,"marketCap":975427241},{"date":"2025-07-03","current":-5.649134,"twenty":-13.4687,"median":-8.851321,"eighty":-5.729733,"marketCap":1013572441},{"date":"2025-07-11","current":-6.060959,"twenty":-13.466131,"median":-8.823918,"eighty":-5.695738,"marketCap":1080599005},{"date":"2025-07-18","current":-7.314861,"twenty":-13.46266,"median":-8.816193,"eighty":-5.710767,"marketCap":1293122259},{"date":"2025-07-25","current":-7.006501,"twenty":-13.460198,"median":-8.785147,"eighty":-5.721214,"marketCap":1257999997},{"date":"2025-08-01","current":-8.237689,"twenty":-13.451559,"median":-8.722056,"eighty":-5.729733,"marketCap":1437436162},{"date":"2025-08-08","current":-8.281316,"twenty":-13.442628,"median":-8.688191,"eighty":-5.747092,"marketCap":1469250645},{"date":"2025-08-15","current":-8.47781,"twenty":-13.428755,"median":-8.660023,"eighty":-5.769982,"marketCap":1662306709},{"date":"2025-08-22","current":-8.638654,"twenty":-13.403956,"median":-8.63053,"eighty":-5.780372,"marketCap":1688336740},{"date":"2025-08-29","current":-8.414646,"twenty":-13.396944,"median":-8.638654,"eighty":-5.787092,"marketCap":1651460863},{"date":"2025-09-05","current":-8.112917,"twenty":-13.396458,"median":-8.622065,"eighty":-5.790869,"marketCap":1589278011},{"date":"2025-09-12","current":-8.597222,"twenty":-13.393909,"median":-8.60362,"eighty":-5.797709,"marketCap":1699182587},{"date":"2025-09-19","current":-8.94501,"twenty":-13.385494,"median":-8.610019,"eighty":-5.800038,"marketCap":1774380454},{"date":"2025-09-26","current":-9.045131,"twenty":-13.370479,"median":-8.627645,"eighty":-5.80289,"marketCap":1777272680},{"date":"2025-10-03","current":-8.512022,"twenty":-13.360301,"median":-8.638654,"eighty":-5.813948,"marketCap":1676044781},{"date":"2025-10-10","current":-8.486281,"twenty":-13.357847,"median":-8.622235,"eighty":-5.817225,"marketCap":1651460863},{"date":"2025-10-17","current":-8.047023,"twenty":-13.353429,"median":-8.597222,"eighty":-5.821028,"marketCap":1580601334},{"date":"2025-10-24","current":-8.513119,"twenty":-13.347233,"median":-8.60362,"eighty":-5.824758,"marketCap":1663029766},{"date":"2025-10-31","current":-8.263348,"twenty":-13.342738,"median":-8.57038,"eighty":-5.828443,"marketCap":1608077478},{"date":"2025-11-07","current":-8.118597,"twenty":-13.33536,"median":-8.561701,"eighty":-5.835563,"marketCap":1576262995},{"date":"2025-11-14","current":-8.953433,"twenty":-13.315064,"median":-8.562935,"eighty":-5.839457,"marketCap":1754134874},{"date":"2025-11-21","current":-8.32101,"twenty":-13.306363,"median":-8.564004,"eighty":-5.842723,"marketCap":1572018786},{"date":"2025-11-28","current":-9.70873,"twenty":-13.305926,"median":-8.567726,"eighty":-5.844642,"marketCap":1843549304},{"date":"2025-12-05","current":-9.421046,"twenty":-13.303031,"median":-8.581097,"eighty":-5.846596,"marketCap":1798727281},{"date":"2025-12-12","current":-8.095034,"twenty":-13.295471,"median":-8.575738,"eighty":-5.852269,"marketCap":1557727706},{"date":"2025-12-19","current":-8.116161,"twenty":-13.29424,"median":-8.562935,"eighty":-5.853536,"marketCap":1560326085},{"date":"2025-12-26","current":-8.732727,"twenty":-13.291734,"median":-8.57038,"eighty":-5.866198,"marketCap":1684398642},{"date":"2026-01-02","current":-9.374295,"twenty":-13.28902,"median":-8.597222,"eighty":-5.876979,"marketCap":1802624848},{"date":"2026-01-09","current":-8.51177,"twenty":-13.280164,"median":-8.575738,"eighty":-5.882433,"marketCap":1623986350},{"date":"2026-01-16","current":-8.766662,"twenty":-13.272619,"median":-8.610019,"eighty":-5.888715,"marketCap":1666209995},{"date":"2026-01-23","current":-9.448662,"twenty":-13.268752,"median":-8.622065,"eighty":-5.894114,"marketCap":1817565522},{"date":"2026-01-30","current":-9.241158,"twenty":-13.264633,"median":-8.634183,"eighty":-5.904462,"marketCap":1805223226},{"date":"2026-02-06","current":-8.459688,"twenty":-13.260074,"median":-8.637068,"eighty":-5.918058,"marketCap":1633080673},{"date":"2026-02-13","current":-8.89399,"twenty":-13.217763,"median":-8.637068,"eighty":-5.918058,"marketCap":1727921476},{"date":"2026-02-20","current":-9.442084,"twenty":-13.195802,"median":-8.637068,"eighty":-5.918058,"marketCap":1818864712},{"date":"2026-02-27","current":-9.418754,"twenty":-13.077142,"median":-8.637068,"eighty":-5.918058,"marketCap":1818864712},{"date":"2026-03-06","current":-8.866459,"twenty":-13.050618,"median":-8.637068,"eighty":-5.918058,"marketCap":1678552291},{"date":"2026-03-13","current":-9.080009,"twenty":-12.99028,"median":-8.637068,"eighty":-5.918058,"marketCap":1713630396},{"date":"2026-03-20","current":-8.989812,"twenty":-12.872607,"median":-8.637068,"eighty":-5.918058,"marketCap":1697390533},{"date":"2026-03-27","current":-9.422218,"twenty":-12.835328,"median":-8.637068,"eighty":-5.918058,"marketCap":1779239445},{"date":"2026-04-02","current":-10.121514,"twenty":-12.76463,"median":-8.637068,"eighty":-5.918058,"marketCap":1913055920},{"date":"2026-04-10","current":-8.614145,"twenty":-12.646197,"median":-8.634183,"eighty":-5.918058,"marketCap":1770589741},{"date":"2026-04-17","current":-9.098299,"twenty":-12.580967,"median":-8.627645,"eighty":-5.918058,"marketCap":1882437117},{"date":"2026-04-24","current":-8.672978,"twenty":-12.531366,"median":-8.627645,"eighty":-5.918058,"marketCap":1784979462},{"date":"2026-05-01","current":-9.840216,"twenty":-12.408666,"median":-8.627645,"eighty":-5.918058,"marketCap":2028296560},{"date":"2026-05-08","current":-9.387238,"twenty":-12.372989,"median":-8.627645,"eighty":-5.918058,"marketCap":1941304156},{"date":"2026-05-15","current":-10.205734,"twenty":-12.288471,"median":-8.627645,"eighty":-5.918058,"marketCap":2008020135},{"date":"2026-05-22","current":-10.228389,"twenty":-12.254036,"median":-8.627645,"eighty":-5.918058,"marketCap":1997554883},{"date":"2026-05-29","current":-10.59007,"twenty":-12.233824,"median":-8.622406,"eighty":-5.917765,"marketCap":2080240286},{"date":"2026-06-05","current":-11.245266,"twenty":-12.202715,"median":-8.627645,"eighty":-5.918058,"marketCap":2203549908},{"date":"2026-06-12","current":-11.54906,"twenty":-12.154142,"median":-8.627645,"eighty":-5.918058,"marketCap":2243259786},{"date":"2026-06-18","current":-12.068208,"twenty":-12.129758,"median":-8.627645,"eighty":-5.918058,"marketCap":2334681645},{"date":"2026-06-26","current":-12.126491,"twenty":-12.093842,"median":-8.622406,"eighty":-5.917765,"marketCap":2326994875},{"date":"2026-07-02","current":-12.298451,"twenty":-12.093842,"median":-8.622406,"eighty":-5.917765,"marketCap":2372416697},{"date":"2026-07-10","current":-13.041486,"twenty":-12.086912,"median":-8.622406,"eighty":-5.917765,"marketCap":2512874946},{"date":"2026-07-17","current":-12.197585,"twenty":-12.086912,"median":-8.622406,"eighty":-5.917765,"marketCap":2352151577},{"date":"2026-07-24","current":-12.127093,"twenty":-12.086912,"median":-8.622406,"eighty":-5.917765,"marketCap":2324199686},{"date":"2026-07-31","current":-12.200057,"twenty":-12.075175,"median":-8.622235,"eighty":-5.917471,"marketCap":2367525116},{"date":"2026-08-07","current":-12.393886,"twenty":-12.081578,"median":-8.622235,"eighty":-5.917471,"marketCap":2407356560},{"date":"2026-08-14","current":-12.119292,"twenty":-12.094187,"median":-8.622235,"eighty":-5.917471,"marketCap":2389761384},{"date":"2026-08-21","current":-12.797528,"twenty":-12.094187,"median":-8.622235,"eighty":-5.917471,"marketCap":2554741973},{"date":"2026-08-28","current":-13.045486,"twenty":-12.094187,"median":-8.622235,"eighty":-5.917471,"marketCap":2597566722},{"date":"2026-09-01","current":-12.262524,"twenty":-12.094187,"median":-8.622235,"eighty":-5.917471,"marketCap":2429777952}],"updateTime":1788388382556},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PHVS\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625953633","title":"Pharvaris Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953633","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953633?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:52","pubTimestamp":1775566320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2026 08:52 ET (12:52 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625677728","title":"Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2625677728","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625677728?lang=en_us&edition=fundamental","pubTime":"2026-04-06 23:14","pubTimestamp":1775488480,"startTime":"0","endTime":"0","summary":"Pharvaris (PHVS) remains well positioned with its lead drug candidate, deucrictibant, supported by upcoming clinical catalysts and strong commercial potential in the hereditary angioedema treatment ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","III","BK4134","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625670541","title":"Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2625670541","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625670541?lang=en_us&edition=fundamental","pubTime":"2026-04-06 23:13","pubTimestamp":1775488380,"startTime":"0","endTime":"0","summary":"Pharvaris enrolled deucrictibant XR for HAE in CHAPTER 3. Positive results could lend 30% upside to the stock, says Guggenheim analyst.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/06/Medical-Research-And-Development-Center-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/06/Medical-Research-And-Development-Center-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/04/51660952/pharvaris-moves-closer-to-new-preventive-treatment-for-rare-swelling-disorder","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/04/51660952/pharvaris-moves-closer-to-new-preventive-treatment-for-rare-swelling-disorder","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625674442","title":"Pharvaris NV reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2625674442","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625674442?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:33","pubTimestamp":1775482418,"startTime":"0","endTime":"0","summary":"Pharvaris NV reports results for the quarter ended December 31 - Earnings SummaryPharvaris NV PHVS.OQ reported a quarterly adjusted loss of 72 cents per share for the quarter ended December 31, lower ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nL8N40P0OM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625676667","title":"RBC Trims Price Target on Pharvaris to $51 From $52, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2625676667","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625676667?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:17","pubTimestamp":1775474236,"startTime":"0","endTime":"0","summary":"Pharvaris (PHVS) has an average rating of buy and mean price target of $48.66, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625611930","title":"Does CHAPTER-3 Enrollment Milestone and Pipeline Progress Change The Bull Case For Pharvaris (PHVS)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625611930","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625611930?lang=en_us&edition=fundamental","pubTime":"2026-04-05 03:20","pubTimestamp":1775330422,"startTime":"0","endTime":"0","summary":"Pharvaris N.V. recently reported full-year 2025 results showing a net loss of €175.7 million, with basic and diluted loss per share from continuing operations of €2.97, while advancing its hereditary angioedema (HAE) pipeline.\nDespite deeper losses, Pharvaris completed enrollment in its CHAPTER-3 pivotal study of deucrictibant XR and stayed on track for a near-term regulatory filing for deucrictibant IR, underscoring the company’s focus on progressing multiple HAE treatment approaches.\nWe’ll...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/does-chapter-3-enrollment-milestone-and-pipeline-progress-ch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/does-chapter-3-enrollment-milestone-and-pipeline-progress-ch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HAE","LU0106261612.USD","LU0205194284.USD","IE00B19Z6F94.USD","LU0012050646.USD","LU1169590202.USD","LU1169589451.USD","BK4198","PHVS","BK4007","PRGS","IE00BLDYK493.USD","BK4097","LU0205193047.USD","IE00B64QTZ34.USD","IE0034390439.USD","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624794657","title":"Pharvaris NV  expected to post a loss of 70 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2624794657","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624794657?lang=en_us&edition=fundamental","pubTime":"2026-04-03 20:37","pubTimestamp":1775219828,"startTime":"0","endTime":"0","summary":"Pharvaris NV  expected to post a loss of70cents a share - Earnings Preview Pharvaris NV PHVS.OQ PHVS.O is expected to  show no change in quarterly revenue when it reports  results on May 11 (estimated","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nL8N40M0ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506733","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506733","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624506733?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:07","pubTimestamp":1775131643,"startTime":"0","endTime":"0","summary":"PMGC  shares were down 67% in Thursday premarket activity, after the company said overnight it was offering roughly $4.6 million of its common shares to Streeterville Capital.Nordson  stock was down 19%, erasing gains from the previous session.Pharvaris  stock was 6.6% lower after the company reported a wider Q4 loss.Lindsay  shares were down 4.7% after the company reported lower fiscal Q2 earnings and revenue that also missed analysts' forecasts.Akamai Technologies  stock was 3.5% lower after Baird downgraded the company to neutral from outperform.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKAM","BK4007","BK4152","LU2286300806.USD","BK4183","BK4554","PHVS","BK4608","NDSN","BK4116","ELAB","LNN","BK4585","BK4161","BK4588","LU1059921491.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624505453","title":"Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2624505453","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624505453?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:34","pubTimestamp":1775129668,"startTime":"0","endTime":"0","summary":"An update from Pharvaris ( ($PHVS) ) is now available. On April 2, 2026, Pharvaris reported fourth-quarter and full-year 2025 results that underlin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pharvaris-posts-2025-results-as-deucrictibant-nears-nda-filing-and-key-phase-3-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pharvaris-posts-2025-results-as-deucrictibant-nears-nda-filing-and-key-phase-3-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624080865","title":"Pharvaris Q4 EPS $(0.84) Misses $(0.69) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2624080865","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624080865?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:57","pubTimestamp":1775127476,"startTime":"0","endTime":"0","summary":"Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.69) by 21.74 percent. This is a 23.53 percent decrease over losses of $(0.68) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/51620660/pharvaris-q4-eps-0-84-misses-0-69-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624721508","title":"Earnings Flash (PHVS) Pharvaris Posts Q4 Loss 0.72 Euro a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2624721508","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624721508?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:54","pubTimestamp":1775127278,"startTime":"0","endTime":"0","summary":"Earnings Flash (PHVS) Pharvaris Posts Q4 Loss 0.72 Euro a Share","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624296508","title":"Pharvaris FY25 loss widens to €176 million; Q4 loss climbs to €46.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624296508","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624296508?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:50","pubTimestamp":1775127024,"startTime":"0","endTime":"0","summary":"Pharvaris posted a full-year 2025 net loss of EUR 176 million, with basic and diluted loss per share of EUR 2.97.Fourth-quarter net loss widened to EUR 46.7 million, translating to a loss per share of EUR 0.72.R&D expenses climbed to EUR 124 million for the year, while fourth-quarter R&D rose to EUR 34.1 million.Cash and cash equivalents increased to EUR 292 million as of Dec. 31, 2025.Enrollment completed in the CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis, with topline data expected in 3Q2026.Submission of the U.S. NDA for deucrictibant IR for on-demand HAE treatment remains on track for 1H2026.CEO Berndt Modig said the RAPIDe-3 Phase 3 readout was a key milestone, with the company focused on executing ahead of the planned NDA filing and CHAPTER-3 data.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLdkKP3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BKPKM429.USD","LU2095319765.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","SG9999014005.SGD","BK4585","IE00BN0W2V16.EUR","PHVS","IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","SG9999014013.SGD","LU2210150020.SGD","BK4588","SG9999014039.USD","BK4007","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624082185","title":"Pharvaris Nv - FY2025 Loss €176 Mln; Basic and Diluted Loss per Share €2.97","url":"https://stock-news.laohu8.com/highlight/detail?id=2624082185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624082185?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:50","pubTimestamp":1775127000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA9FWX78:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624508204","title":"Press Release: Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624508204","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624508204?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:50","pubTimestamp":1775127000,"startTime":"0","endTime":"0","summary":"for prophylactic treatment of HAE attacks; topline data anticipated in. -- Timeline for submission of NDA dossier of deucrictibant IR for on-demand. treatment of HAE attacks remains on-track in 1H2026. \"The positive readout of our first pivotal Phase 3 study, RAPIDe-3, at the end of 2025 was a crucial moment for Pharvaris. With the momentum of this important milestone, we continue to execute in 2026 through the anticipated NDA submission of deucrictibant IR for the on-demand treatment of HAE attacks, topline data readout of CHAPTER-3, and enrollment in CREAATE,\" said Berndt Modig, Chief Executive Officer of Pharvaris. \"Across all our programs, Pharvaris remains committed to helping to improve standard of care for those living with bradykinin-mediated angioedema. In addition to potentially bringing deucrictibant to those with HAE type 1 and type 2, we hope to also address unmet needs of those with HAE with normal C1 inhibitor and acquired angioedema with C1 inhibitor deficiency. Our tea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHVS","TM","BK4555","IE0034390439.USD","BK4588","LU1169590202.USD","LU0205194284.USD","LU0106261612.USD","IE00B19Z6F94.USD","LU0012050646.USD","BK4585","IE00B64QTZ34.USD","IE00BLDYK493.USD","HAE","BK4099","03160","BK4604","BK4007","LU0205193047.USD","LU1169589451.USD","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623308354","title":"Assessing Pharvaris (PHVS) Valuation After Recent Share Price Pullback And Strong Longer Term Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2623308354","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623308354?lang=en_us&edition=fundamental","pubTime":"2026-03-29 23:06","pubTimestamp":1774796774,"startTime":"0","endTime":"0","summary":"Event context and recent share performance\nPharvaris (PHVS) shares recently closed at $27.35, with the stock showing mixed short term moves, including a modest 1 day decline and a small pullback over the past month after earlier gains in the past 3 months and year.\nSee our latest analysis for Pharvaris.\nThe recent pullback in Pharvaris’s share price comes after a strong 1 year total shareholder return of 73.10% and a 3 year total shareholder return of 239.54%. However, the 5 year total...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/assessing-pharvaris-phvs-valuation-after-recent-share-price","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/assessing-pharvaris-phvs-valuation-after-recent-share-price","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622107082","title":"BioCryst Shares Remain Undervalued, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2622107082","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622107082?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:18","pubTimestamp":1774451926,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals  remains undervalued even with  a recent price increase due to unconfirmed reports of being a takeover target, RBC Capital Markets said in a Wednesday note.Even with the shares up 24% year-to-date, RBC's analysis of BioCryst in various takeout scenarios and as an independent company all projected share prices that are higher than what they are currently. The scenarios made various assumptions about the peak revenue for the company's hereditary angioedema treatments Orladeyo and Navenibart, as well as the potential discounted cash flow takeout value.RBC analysts said their analysis forecast the company's share price at $18 per share in the base case, $20 per share in the bull case, and $12 per share in the bear case.Even with the potential impact of rival Pharvaris'  Q3 data for its competing hereditary angioedema drug, Orladeyo is still likely to have a \"meaningful\" role in disease treatment, while Navenibart could see a growing role among the longer-acting pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4547","BK4139","PHVS","BCRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621764744","title":"Is It Too Late To Consider Pharvaris (PHVS) After A 3.5x Three Year Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621764744","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621764744?lang=en_us&edition=fundamental","pubTime":"2026-03-23 06:10","pubTimestamp":1774217454,"startTime":"0","endTime":"0","summary":"If you are wondering whether Pharvaris at around US$26 a share still offers value, it helps to step back and look at what the recent returns and current valuation are really telling you.\nThe stock has delivered a 68.8% return over the past year and a very large 3 year gain of around 3.5x, even though the year to date return is a 1.8% decline and the 30 day return is a 7.5% decline. This can change how the risk and reward balance feels right now.\nRecent headlines around Pharvaris have focused...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/is-it-too-late-to-consider-pharvaris-phvs-after-a-35x-three","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/is-it-too-late-to-consider-pharvaris-phvs-after-a-35x-three","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620806377","title":"Pharvaris announces publications of efficacy, safety evidence on deucrictibant","url":"https://stock-news.laohu8.com/highlight/detail?id=2620806377","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620806377?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:55","pubTimestamp":1774004134,"startTime":"0","endTime":"0","summary":"Pharvaris (PHVS) announced that two articles have been published back-to-back in the same issue of The Lancet Haematology. The articles detail data...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pharvaris-announces-publications-of-efficacy-safety-evidence-on-deucrictibant-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pharvaris-announces-publications-of-efficacy-safety-evidence-on-deucrictibant-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620870037","title":"Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema","url":"https://stock-news.laohu8.com/highlight/detail?id=2620870037","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620870037?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:53","pubTimestamp":1774004038,"startTime":"0","endTime":"0","summary":"Pharvaris reported that two articles in The Lancet Haematology published results from the randomized Phase 2 CHAPTER-1 and RAPIDe-1 studies of deucrictibant, an oral bradykinin B2 receptor antagonist being developed for hereditary angioedema.CHAPTER-1 evaluated prophylaxis and showed a statistically significant reduction in attack occurrence versus placebo, with deucrictibant reported as well tolerated at both doses tested.RAPIDe-1 evaluated on-demand treatment and showed statistically significant reductions in attack severity versus placebo and reduced time to symptom relief and resolution, with deucrictibant reported as well tolerated at all doses tested.Topline data from the Phase 3 CHAPTER-3 prophylaxis study are expected in Q3 2026.Confirmatory Phase 3 RAPIDe-3 on-demand data were already presented at the American Academy of Allergy, Asthma & Immunology 2026 Annual Meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Whi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL78GY3F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620266013","title":"Pharvaris NV director Robert Glassman files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620266013","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620266013?lang=en_us&edition=fundamental","pubTime":"2026-03-19 02:24","pubTimestamp":1773858264,"startTime":"0","endTime":"0","summary":"Robert Glassman, a director at Pharvaris, filed an initial statement of beneficial ownership reporting 15,167 shares of common stock. The filing also reported stock options covering 16,500 shares at an exercise price of USD 28.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL8XJDGq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":114,"code":"91000000","status":"200"}]}}